Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Puma Biotechnology Inc News

    5,07 $ +3,89% +0,19 $
    In : 4,7407 € | 19:17:30 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1J643
    ISIN: US74587V1070
    US-Symbol: PBYI
    Typ: Aktie

    Puma Biotechnology Inc News

    18.04.24 - Businesswire
    Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the ...
    03.04.24 - Businesswire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Puma’s Board of Directors approved ...
    20.03.24 - Businesswire
    Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational ...
    29.02.24 - Businesswire
    Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise ...
    27.02.24 - Businesswire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 26, 2024, the Compensation Committee of Puma’s Board of Directors ...
    22.02.24 - Businesswire
    Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will ...
    15.02.24 - Businesswire
    Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 29, 2024, following the ...
    13.02.24 - Businesswire
    Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial (PUMA-ALI-4201; ...
    18.01.24 - PR Newswire
    Thinking about buying stock in Marpai, Phunware, Spirit Airlines, BigBear.ai, or Puma Biotechnology?
    Thinking about buying stock in Marpai, Phunware, Spirit Airlines, BigBear.ai, or Puma Biotechnology? PR Newswire
    13.01.22 - PR Newswire
    Thinking about buying stock in iSpecimen, Rockwell Medical, Puma Biotechnology, Bumble, or Nikola Corp?
    Thinking about buying stock in iSpecimen, Rockwell Medical, Puma Biotechnology, Bumble, or Nikola Corp? PR Newswire
    12.08.19 - PR Newswire
    Cellulite Treatment Market Projected to Reach $1,438.5 Billion by 2026
    Cellulite Treatment Market Projected to Reach $1,438.5 Billion by 2026 Financialnewsmedia.com News Commentary PR Newswire
    18.06.18 - PR Newswire
    Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies
    Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-​clinical PDX Studies PR Newswire
    22.11.17 - PR Newswire
    New Early- Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia Following License Deal
    New Early- Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia Following License Deal - Specialised Therapeutics Asia to make NERLYNX® ...
    13.11.17 - Der Aktionär
    Puma Biotechnology: Einstiegschance beim heißen Übernahmekandidaten
    03.10.17 - PR Newswire
    Lifshitz & Miller LLP Announces Investigation of Equifax Inc., Intercept Pharmaceuticals, Inc., Inventure Foods, Inc., Puma Biotechnology, Inc., Tintri, Inc., Twenty-First Century Fox, Inc. and Ub
    Lifshitz & Miller LLP Announces Investigation of Equifax Inc., Intercept Pharmaceuticals, Inc., Inventure Foods, Inc., Puma Biotechnology, Inc., Tintri, Inc., Twenty-​First Century Fox, Inc. ...
    30.09.17 - Der Aktionär
    Top-Dividendenzahler Roche: Hoffnung auf Zulassung - FDA prüft im Schnellverfahren
    04.08.17 - PR Newswire
    PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. - PBYI
    PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. - PBYI ...
    19.07.17 - Der Aktionär TV
    Puma Biotechnology - Große Phantasie ist kurzfristig erstmal raus
    Genauso wie Vertex ist auch Puma Biotechnology eine Beteiligung von BB Biotech, allerdings eine vergleichsweise kleine. Dennoch kann man sich darüber freuen, dass auch ...
    19.07.17 - Der Aktionär TV
    Marion Schlegel: Vertex, Puma Biotechnology und Morphosys in der Analyse
    Marion Schlegel vom Anlegermagazin DER AKTIONÄR blickt in dieser Sendung auf die Pharma- und Biotechbranche. Heute geht es um Vertex, Puma Biotechnology und ...
    18.07.17 - Der Aktionär
    BB Biotech: Mini-Beteiligung Puma Biotechnology gelingt der Durchbruch

    Newssuche

    Videos

    newspaper
    08:40 Uhr +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »